Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
To date, no head-to-head trial has compared the prevention methods.
The vaginal ring, approved in Europe, is not yet available in the United States.
The safety trial will enroll pregnant women in several sub-Saharan African nations.
This finding suggests that the HIV-preventing vaginal ring that awaits regulatory approval may achieve widespread use.
Poised for regulatory approval, the monthly vaginal ring appeared to lower the risk of HIV by about 39% overall in a recent study.
A three-month vaginal ring could help prevent HIV in women.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.
The open-label follow-up to a previous placebo-controlled study of an HIV-preventing ring is seeing high use among women.
A one-month version of the ring is currently up for regulatory approval.
Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.
A recent study found that the antiretroviral-containing ring was safe and that the girls in the trial used it well.
A look at the most notable HIV-related studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle.
A major study’s finding has assuaged concerns that HIV drugs can compromise how well birth control works.
However, for some in a recent study, the anxiety that their partner would discover the ring reduced sexual enjoyment.
Women who used the monthly ring at high levels benefited from a significant HIV risk reduction.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.